Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Or perhaps you could say that I have been there and done that with this company. I am not trying to be a know-it-all with regard to the SEC as others here clearly are. I do know, however, of an individual on the verge of filing a lawsuit that will blow this company out of the water and expose it for all to see in ways you cannot imagine.
The SEC has absolutely no interest in Pink Sheet companies, and as you admitted, this is purely your own opinion and speculation. Why put your opinion out there as "fact"???
Show me some kind, any kind, of documentation that there is an "SEC's new aggressive stance" on Pink Sheet stocks please.
Before you accuse people of having ulterior motives, maybe ask where they got their information from.
http://www.sec.gov/answers/pink.htm
Pink Sheets
Pink OTC Markets, formerly known as Pink Sheets, operates Pink Quote, an electronic quotation system that displays quotes from broker dealers for many over-the-counter (OTC) securities. "Market makers" and other brokers who buy and sell OTC securities, can use the Pink Quote to publish their bid and ask quotation prices. The name "Pink Sheets" comes from the color of paper they were historically printed on. They are published electronically today by Pink OTC Markets Inc., a privately owned company. Pink OTC Markets Inc. is not registered with the SEC in any way and it is not the Financial Industry Regulatory Authority (FINRA) Broker-Dealer. Pink OTC Markets Inc. does not require companies whose securities are quoted upon its systems to meet any listing requirements. With the exception of a few foreign issuers, the companies quoted in Pink Quote tend to be closely held, extremely small and/or thinly traded. Most do not meet the minimum listing requirements for trading on a national securities exchange, such as the New York Stock Exchange or the Nasdaq Stock Market. Many of these companies do not file periodic reports or audited financial statements with the SEC, making it very difficult for investors to find reliable, unbiased information about those companies. For all of these reasons, companies quoted in Pink Quote can be among the most risky investments. That's why you should take extra care to thoroughly research any company quoted exclusively in the Pink Quote. Be aware that some broker-dealers are required by Rule 15c2-11 under the 1934 Act to have some information about the issuer. Ask your broker-dealer whether it has any Rule 15c2-11 information before you invest.
The OTC Bulletin Board (OTCBB) eligibility rule required companies whose securities were quoted on the OTCBB to file updated financial reports with the SEC or with their banking or insurance regulators. If these companies failed to file current financial reports, their securities would be removed from the OTCBB, but could be quoted in another system, such as Pink OTC Markets’ Pink Quote inter-dealer quotation service. The eligibility rule was phased in over a 12-month period and ended June 22, 2000. On the OTC Bulletin Board's website, you can find a history of the rule and data concerning companies that were removed from the OTCBB. If you are considering investing in a company that trades on the OTCBB, you can find reports filed by the company on the SEC's EDGAR database.
For more information about the OTCBB, please read "OTC Bulletin Board" in our Fast Answers database.
http://www.sec.gov/answers/pink.htm
To the best of my knowledge, the SEC keeps Pink Sheet Stocks at arm's length. You need to complain to PinkSheets, which is not so simple as the SEC complaint sheet.
TA is gagged..
Transfer Agent
Interwest Transfer Company, Inc. (gagged)
1981 East 4800 South
Suite 100
Salt Lake City, UT 84117
Phone: (801) - 272-9294
Fax: (801) - 277-3147
Simple for all to now take notice that "ib" has stated their position is that they have shorted the stock, and any information put out is clearly prejudiced toward seeing the PPS go lower.
I also have proof, through a third party, that information was released that was false and misleading on another matter.
The hiring of an auditor, if none was actually hired, would fit this to a tee!
It is going to be more than that - remember, he is on Administrative Hold (ie: bounced a check)
https://esos.state.nv.us/SOSServices/AnonymousAccess/CorpSearch/CorpDetails.aspx?lx8nvq=21SjGadQZLyYT5wu0eLdfA%253d%253d
Calculate Reinstatement Fees for
SOMATIC SYSTEMS, INC.
Item Fee
Reinstatement Fee $ 300.00
Annual List (due 3/31/2008) File This List Online Now! File Offline
$ 2,575.00
Annual List Late Fee $ 75.00
Annual List (due 3/31/2009) File This List Online Now! File Offline
$ 2,575.00
Annual List Late Fee $ 75.00
TOTAL*
$ 5,600.00
* These fees are current as of today's date of 07/22/2009 11:30 AM but can change based on events occurring on future dates. Calculated fees do not include fees and penalties if the entity is in default or revoked status due to resignation or other registered agent deficiency or is on administrative hold. For these types of inquiries please contact our office.
Hmmmm....... market is open for almost 30 minutes now, did I miss something?
all over the map it seems... I think it was just yesterday I read something like "read it and wep" (Assume that was supposed to say weep)
Apparently, you need to ask a lot more.... What do you think the annual fee is? Do you know the progress on getting insurance to cover the cost? If it is YOUR child, are you going to take the chance that you are in the 50-70% of compatible matches, or are you going to be sure it is 100% by banking your own child's blood?
Yes, this is free, but it is also a donation. They will not bank cord blood for your (your child's) use later on in life should they need it. This is a wonderful idea, like a blood bank for the use of the community - but if you need them later, you have to hope there is a match out there for you as well.
Aetna has the contract for the "North", not the Northeast - the States affected are... "The North Region includes the District of Columbia and the states of Connecticut, Delaware, Illinois, Indiana, Iowa (Rock Island Arsenal area only); Kentucky (except the Fort Campbell area); Maine, Maryland, Massachusetts, Michigan, Missouri (St. Louis area only); New Hampshire, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, and Wisconsin."
The only way that this could have any impact on SMAS is if Steve has a connection at Aetna - certainly there was no relationship ever developed with Tricare.
Cord Blood America Highlights Significant 2009 Progress
SANTA MONICA, Calif. and LAS VEGAS, July 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today said its accomplishments in the first half of 2009 are the most significant in the Company's history and Cord Blood America is progressing to its goal of being the most important company in stem cell storage in the world.
January 6 - Launched the first social media campaign in the industry to start a public conversation about the potential usefulness of stem cells and the importance of storing umbilical cord blood stem cells.
January 9 - Established its three pillars of success for 2009: Organic growth, acquisitions and debt reduction leading to a healthy balance sheet.
February 9 - The Obama Administration announces its plan and support of stem cell research in the United States; Cord Blood America is listed on the ETF Innovators Stem Cell 40 company index.
February 12 - CBAI announces $1 million reduction in long term debt.
February 25 - CBAI announces restructuring of long term debt to free up cash flow for the company.
March 5 - CBAI noted as the top stock performer on ETF Innovators Stem Cell index, with a year-to-date stock price increase of 279 percent.
April 5 - Congress introduces legislation to promote Family Banking of Umbilical Cord Blood stem cells; CBAI announces its total long term debt reduction at $1.75 million.
April 9 - CBAI announces its first customer in Germany, noting its dedication to organic growth.
April 23 - CBAI announces additional debt reduction of $817,000.
May 7 - CBAI says it will acquire or build its own stem cell processing and storage laboratory, eliminating the need to outsource lab services and projecting a significant increase in gross profit once complete.
May 14 - CBAI announces it received a $2.3 million commitment to finance the building of its stem cell lab.
May 27 - CBAI announces debt has been reduced by $4.194 million in 2009.
June 11- CBAI announces additional expansion in Europe.
June 22 - CBAI announces contracting independent affiliate to sell services in Caribbean and Central America.
Since the end of the mid-point of 2009, Cord Blood America has further secured $7.5 million in long term equity financing for growth and acquisition opportunities; announced it has begun building the one of the largest stem cell labs in the U.S.; and announced hiring of an experienced, successful management team to manage its new laboratory
"On January 6, 2009, the closing CBAI stock price was $0.0017. On July 10, 2009, the closing stock price was 0.0033, a 94% increase in 6 months of trading. That's not where we want to be, we are still very undervalued, and I understand that the day-to-day swings of our very liquid and volatile stock price cause some investor concern," said Matthew Schissler, Chairman and CEO. "I tell investors to take a snapshot of the last six months, not six hours. Micro cap stocks are perhaps not for the faint of heart. We believe we're building a very valuable company and this snapshot of the past six months shows our progress."
"In January, CBAI stated its mission is to lay the foundation for a much stronger healthier company by the end of 2009, which included organic growth, acquisition and debt reduction. As you can see by these highlights, we remain laser-focused on executing these strategies," Mr. Schissler said. "Because of our focus, we were able to raise significant funding to build a lab with the future growth opportunities it affords us. We are also pleased by the current support of stem cell research in Washington, D.C. and Congressional and state legislative focus on family stem cell banking legislation."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
You didn't miss anything - there is nothing there that relates to either Leading Points or SMAS. It is simply the author's wishful thinking based upon the fact that the two entities are only 26 miles apart. I am less than 26 miles from West Point, so by that logic I will soon be the Commander there - can't wait!!
Maybe I am missing something here - can you explain to me what Tricare awarding subcontractor contracts to insurance companies throughout the country has to do with Leading Points, let alone SMAS??
WOW - this is a CEO? "predicting the outcomes of television shows with pinpoint accuracy" is one of his "superpowers"???
My superpower
Remembering events and people to the day back 20 years; predicting outcomes of television shows with pinpoint accuracy; retention of humidity.
Interests
Fine Art, Design, Architecture, Software Design, Interface and Information Design, Organizational Design, Spatial Design, Ecology, Movies, Classic Cars especially British Classic Cars.
MORE at http://www.google.com/profiles/saronstein
Cord Blood America (OTC BB: CBAI) Discusses Umbilical Cord Blood Stem Cell and Juvenile Diabetes Research
-- Tipping Point for New Wave of Customers --
67 WALL STREET, New York - July 15, 2009 - The Wall Street Transcript has just published its Life Science Tools/Medical Laboratories Report report offering a timely review of the sector to serious investors and industry executives. This 44 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
In the following brief excerpt from the 44 page report, Matthew Schissler, founder of Cord Blood America, discusses the outlook for the sector and for investors.
TWST: What about the technology side? What do you guys do?
Mr. Schissler: We privately bank umbilical cord blood stem cells for families. What that means is families pay us to store the stem cells that are a perfect match for the child. The stem cells are harvested from the umbilical cord at the time of birth so they're non-controversial stem cells. The stem cells are then shipped to our cryogenic facility in New Jersey where they're processed and then cryogenically frozen, so if - God forbid - the child comes down with a future disease that can be battled with stem cells, they'll have a perfect match thus they won't have to find a donor or go to a registry and wait for a donor or whatever it may be. They already have their own perfectly matched set of stem cells to be used to battle disease such as cancer and leukemia.
TWST: Are you finding that as people know about stem cell storage, it's becoming much more popular? Has there been a spike in the use of stem cell storage?
Mr. Schissler: It's interesting. From about 2000 to 2005, there was a spike in families starting to store, and from about late 2005 early 2006 till 2009, that spike has leveled off to about somewhere around 4% of all families in the United States who privately bank their stem cells when they have children. It hasn't really grown that much in the last three or four years. Now, what we attribute this to are two things. One, it always tend to be a certain demographic that stores their stem cells, it tends to be the same people that will do anything for their children from private schools to everything else, and because there is no new developments yet that have been commercialized, there is a lot of things in clinical trials, but there is no new stem cell development being commercialized, there has not been another tipping point in the industry. Let me just give you example. At the University of Florida right now, there is a study going on to see if umbilical cord blood stem cells can treat and cure juvenile diabetes. If that does get through trials and end up becoming commercialized, there is a much larger population that has a history of diabetes in the family than they do cancer and leukemia. Now you're going to have a much larger population saying, "Okay, this might be a good idea for us to store stem cells" and we believe that's going to be the next tipping point. I think over the next three to ten years you're going to see many new therapies get to market and as those therapies get to market, those therapies are going to affect more and more families and you're going to start seeing a much higher percentage of family storing their stem cells.
TWST: Looking at therapies for diabetes for example, is it accurate that the more research there is in stem cells, the more knowledge about stem cells, the more people who want to store stem cells?
Mr. Schissler: Yes, I'll tell you there is actually a much larger theme here. The theme is that within the United States, the previous administration didn't ban stem cell research, they said they were not going to fund stem cell research and what this administration is saying is "We're going to provide government funds for embryonic stem cell research." So, what they're doing is they're putting money and it hasn't happened yet, but they intend to put money into research of embryonic stem cells, which allows us to push therapies to market faster. The reason that's a much larger theme is that other countries have been funding embryonic stem cell research for years, and now some of the countries are ahead of us in certain technologies and what does that mean. That means if they get a technology to market faster, they're going to patent it in the United States. Now every time a procedure is done in the United States using stem cells for that particular affliction, that money ends up in patent royalties ends up going overseas. It's a much larger economical question, but United States basically was building a house without a hammer in previous years, now we've been provided all the tools to at least compete with other countries for stem cell therapy.
Other Companies included in the special section include: Affymetrix, AstraZeneca (AZN), Beckman Coulter (BEC), Bio-Rad Laboratories (BIO), Cardiovascular Systems (CSII), Cepheid (CPHD), Gen-Probe (GPRO), ICU Medical (ICUI), Illumina (ILMN), Immucor (BLUD), Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), Life Technologies (LIFE), Luminex (LMNX), Mettler Toledo, Millipore (MIL), Myriad Genetics (MYGN), Pfizer (PFE), Qiagen (QGEN), Thermo, Waters, Zoll Medical (ZOLL).
This PR is a year old now, does anyone know if it has happened yet?
Somatic Systems, Inc. to Become Nationally Certified Training Program
NORTHAMPTON, MA, July 31, 2008-- Somatic Systems, Inc. is proud to announce the near completion of the application process to become the first Clinical Somatic Education school licensed by the National Certification Board for Therapeutic Massage & Bodywork (NCBTMB).
The NCBTMB is the national, accredited regulatory agency for movement therapy and therapeutic massage professionals, operating the national certification process and examinations that are mandatory for most practitioners to work and to obtain state approval to operate. The NCBTMB is considered the single most influential organization in the massage therapy world today, with only a few massage professionals who are not affected by its regulations.
A critical part of this ongoing certification process requires massage therapists to complete regular continuing education programs throughout their entire careers (generally every four years), and these continuing education programs must be licensed by the NCBTMB. This is the credential that NCBTMB approval will grant Somatic Systems' Clinical Somatic Education Professional Training Program.
While Somatic Systems' training program caters to and is marketed to a wide variety of demographics, including physical therapists, chiropractors, and physicians, obtaining this role in the field of professional massage as well is a highly lucrative opportunity for the company. There are approximately 100,000 massage therapists in the US, with over 130 million visits to massage therapists annually, generating $11 billion in revenue.
Somatic Systems' Clinical Somatic Education program is the company's highest revenue generating service, currently priced at $12,000 per student (up from $9,850 per student last year). Since Somatic Systems began the Clinical Somatics program in 2003, enrollment has grown by 50% each year. NCBTMB licensure of Somatic Systems' Clinical Somatics program as provider of the mandatory continuing education credits for all these massage therapists will provide unprecedented growth and revenue opportunities for Somatic Systems.
Adding this credential to Somatic Systems' training program continues to build its rapidly growing reputation and presence in the health care field. It also complements and paves the way for Somatic Systems' larger strategy of offering continuing education credits to physical therapists, chiropractors, and other health care practitioners, bringing even greater growth in enrollment and revenue opportunities.
"In tough economic times, health care practitioners have to make tough decisions about how they spend their dollars and allocate their time. The most powerful thing a company can do in a tight marketplace is become mandatory -- a necessity for all segments of its markets, not just
a luxury. NCBTMB credentialing means that Somatic Systems provides this mandatory service for massage therapists across the nation. This then enables Somatic Systems to secure itself just such a position, and to be the only such company in the world doing so using the powerful, proprietary, and un-paralleled Clinical Somatics pain management method," stated Somatic Systems CEO Steven Aronstein. "We expect a dramatically expanded customer base to then spread further awareness of our exciting program, and thus continue to multiply even more new training customers and locations."
This development in the company's training program plays into a larger expansion strategy Somatic Systems is pursuing this year, including the forthcoming television shows about the company and their proprietary Somatics products and services (being aired nationally on WE TV, the Travel Channel, and in syndication later this year). Other efforts in this strategy include expanded aggressive branding campaigns, new websites, public relations campaigns, and multiple books to be published about Somatics in the coming year; as well as exclusive licensure of ClinicalSomatics training by the Department of Education, and Masters and Ph.D. accreditation of Somatic Systems' programs (which not only provides even greater notoriety for Somatics Systems' clinical offerings, but also generally enables a training program to charge tuition rates of approximately $25,000 for the same services provided for the company's current $12,000 tuition price).
About Somatic Systems, Inc.
Somatic Systems is the worldwide center for Clinical Somatics(TM), the ground-breaking drug-free, non-surgical approach to pain relief. This proprietary system uses natural, non-invasive movement techniques -- conducted through one-hour hands-on sessions, therapeutic exercises classes, and home exercises lasting as little as 5 minutes a day -- to relieve pain and limitation resulting from accident, trauma and repetitive stress, including back pain, knee pain, joint problems, carpal tunnel syndrome, TMJ, scoliosis, bursitis, sciatica, headaches, tendonitis and more. Clinical Somatics(TM) also provides performance gains and injury prevention for casual and professional athletes.
Somatic Systems is pursuing a 3-part growth strategy, consisting of a nationwide rollout of pain management Somatics Clinics; increased production and distribution of therapeutic videos, books, and other retail self-help Somatics Products; and expanded Somatics Training Programs to supply Clinic practitioners serving medical and orthopedic professionals
and institutional and corporate programs. The company operates a suite of web sites offering Somatics information, products, resources, and opportunities, at www.somatics.org.
Contact:
For more information visithttp://www.somatics.org
or contact:
Investor Relations
1 877 586-2555
I believe that point has been addressed many times. CBAI stores cord blood - there is not going to be any grant money available for this as there is no research being conducted. That is not to say that CBAI would not benefit from grant monies given to other companies for their research as it lifts the sector as a whole. So in answer, they would not be affected directly, but would likely benefit indirectly.
Yes, I knew that, thank you. My post was to point out that there was no research being done by CBAI that I was aware of.
The conversation here has become childish rather than constructive. Can we please all agree that there are reasons to be optimistic from some points of view, and pessimistic from some others - no matter which side you are are on there are valid arguments on the other side. I value both sides of the fence, so please lets stick to the facts and opinions, rather than the name calling, and we could probably all benefit to a much greater extent.
What type of stem cell research have you seen that CBAI is involved in?
Mick, thanks for all of your research and input! Just want to point out one correction that needs to be made. As far as I am aware, CBAI is not involved in doing any of the research on stem cells.
Is there anyone else who has made a loan to Somatics, or Steve, who has not been repaid per the terms of their agreement? I am considering legal remedy, and if there are other individuals in this position then there will be a greater opportunity to recover damages as well.
If you are not comfortable posting here, you can reply to smas.investor@gmail.com
unfortunately, due to the dilution - the major shareholders are most surely the people who got those 10 billion shares
United Spinal Association Reports Positive Results of Stem Cell Transplantation to Treat Multiple Sclerosis: Study May be Key to Unlocking a Cure
NEW YORK, May 8 /PRNewswire-USNewswire/ -- An article published in the Summer 2009 edition of Multiple Sclerosis Quarterly Report, a joint publication of United Spinal Association (www.UnitedSpinal.org) and the North American Research Committee on Multiple Sclerosis (NARCOMS), highlights the positive initial results of patients who have improving neurologic function after receiving a stem cell transplant, despite no longer taking any MS medications.
The results are reported in a National Institutes of Health (NIH)-sponsored study called HALT-MS to confirm whether high-dose immunosuppression followed by autologous stem cell transplantation will prevent MS attacks in patients who are not responding to available treatment options and ultimately protect against the degeneration of nerve fibers.
The article, written by George H. Kraft , MD, MS, director of the Western MS Center in Seattle, Washington, and colleagues, reveals the promising outcomes of the first three patients entered into the HALT-MS Study, including a 27-year-old woman with an 8-year history of relapsing MS who was treated with five different MS drugs, but continued to have relapses.
The study involves wiping out the patient's immune system through high-dose chemotherapy or other means, such as radiation, to destroy most blood cells and bone marrow. Blood "stem cells" with the capacity to generate new blood and immune cells are then transplanted into the patient. These stem cells can either be the patient's own or those from a matched donor. Once the cells are transplanted, they repopulate the bone marrow and restart building all the cell types found in the blood, a process called "engraftment". After transplantation, the patient would effectively have a "new" immune system that would not attack nerves in the brain and spinal cord as seen in MS.
Currently, there are approximately 400 patients with MS worldwide who have been treated with stem cell transplantation. Research demonstrates that patients with highly active forms of relapsing-remitting MS have responded best to treatment.
*****
YOURHEALTHZONE
Curing Diabetes
South Korea
A team of South Korean scientists has grown pancreatic beta cells, which can help treat diabetes, from stem cells taken from the umbilical cord blood of newborn babies.
********
New Hope for Sickle Cell Anemia Patients; Umbilical Cord Blood Stem Cells
BACKGROUND: Sickle cell anemia is one of the most common genetic diseases in the United States, affecting about 70,000 Americans. The disease also afflicts millions of people worldwide, says the National Heart, Lung and Blood Institute. Not everyone who carries the disease shows signs of it. That means about 2 million Americans, or one in 12 African Americans and one in 16 Hispanic Americans, carry the sickle cell trait, says the American Sickle Cell Anemia Association. Sickle cell anemia takes place when hemoglobin -- a component of red cells in the blood -- is defective and causes red blood cells to become stiff and assume a sickle shape. Since these oddly shaped red blood cells can't fit through small blood vessels, they stack up and cause blockages that deplete the supply of oxygen to organs and tissue. In addition, sickle-shaped red blood cells die after about 10 to 20 days, whereas normal red blood cells last about 120 days. That means the cells can't be replaced fast enough, and anemia takes place.
A LIFELONG BATTLE: Sickle cell anemia is a painful condition and often cuts life short. However, the life expectancy of those with the disease is improving. The National Heart, Lung and Blood Institute says sickle cell disease patients now live into their 40s or 50s and longer. A 1994 New England Journal of Medicine study found 50 percent of those with sickle cell anemia lived past 50. It also found most of those who died from the disease died during an acute episode of pain, chest syndrome or stroke. Those are three of the major complications that can occur with sickle cell anemia. Because sickle-shaped cells die too quickly, jaundice and gallstones are common in people with the disease. The limited blood flow caused by sickle cell anemia can result in lung tissue damage and priapism, or painful, prolonged erection. Other organs that can be damaged by the disease include the kidney, liver and spleen. Complications of sickle cell disease also include hand-foot syndrome, which occurs when blood flow is limited in the hands and feet, and delayed growth. When sickle cell anemia damages the spleen, the patient is more vulnerable to infections. This is why the most common cause of death in children with the disease is pneumonia.
TREATMENT: Treatments for sickle cell are mainly aimed at reducing pain and preventing complications like infections and anemia. Pain is most often treated with over-the-counter medicine and heating pads. During episodes of severe pain, fluids and pain-killing medicines like narcotics are administered in the hospital. To prevent infections in babies and young children, parents are often advised to give daily doses of penicillin. Patients with severe sickle cell anemia may need to receive a medicine called hydroxyurea, which reduces the number of painful crises that take place. Blood transfusions are commonly used to treat worsening anemia and complications associated with the disease.
REPLACING BAD BLOOD: The only cure for sickle cell anemia that exists is bone marrow transplantation, but this only works in a small number of cases. Recent research has looked into ways to make the treatment more widely available and make the process safer. A recent study at the Children's Hospital of Pittsburgh looked into a form of bone marrow transplantation that uses reduced-intensity conditioning prior to the transplant. The goal of conditioning is to prepare the body to receive something foreign, like donor bone marrow. The preparation itself carries complications like organ damage and sterility. Reduced-intensity conditioning reduces the risk of these complications by using lower doses of drugs. This type of conditioning makes bone marrow transplantation available to patients with severe sickle cell disease, who already have compromised immune systems. Another study is ongoing at St. Louis Children's Hospital that is incorporating reduced-intensity conditioning. The study is also allowing patients with severe sickle cell disease to receive bone marrow and umbilical cord blood.
FOR MORE INFORMATION, PLEASE CONTACT:
Jackie Ferman-Grothe
St. Louis Children's Hospital
(314) 286-0304
In the filing he states that they only need 5 extra days - guessing it is a 'doesn't matter'
Calculate Reinstatement Fees for
SOMATIC SYSTEMS, INC.
Item Fee
Reinstatement Fee $ 300.00
Annual List (due 3/31/2008) File This List Online Now! File Offline
$ 2,575.00
Annual List Late Fee $ 75.00
Annual List (due 3/31/2009) File This List Online Now! File Offline
$ 2,575.00
Annual List Late Fee $ 75.00
TOTAL*
$ 5,600.00
* These fees are current as of today's date of 05/06/2009 04:29 AM but can change based on events occurring on future dates. Calculated fees do not include fees and penalties if the entity is in default or revoked status due to resignation or other registered agent deficiency or is on administrative hold. For these types of inquiries please contact our office.
From Nevada SOS https://esos.state.nv.us/SOSServices/AnonymousAccess/CorpSearch/FeeDetails.aspx?ctok=21SjGadQZLyYT5wu0eLdfA%253d%253d
Except that WE are the ones that just paid off that debt folks - looks like it was paid off with shares... "CBAI and YA Global Investments agreed on a one time common share settlement for liquidated damages in connection with assigning the outstanding principal and interest to the existing investor."
The date on the approval of the increase in A/S was yesterday - obviously that is why he finally cured the default, to be able to reissue shares.
I sure hope he got at least $250K for them!!!
they have gone from A/S to O/S ALREADY?????
Gucci - did you reach him at the office? Seems like an unimportant question, but I received an email from him at 10:01 which said, in its entirety... "I'm out of the office until the afternoon, and not able to call or email until then. I will get back to you later today." I just want to know if that was the truth. TIA
Cord Blood America CEO Matthew Schissler Teaches Stem Cells
Middle-schoolers learn about stem cells
DYLAN SLAGLE/STAFF PHOTO
Matthew Schissler, of Cord Blood America, takes questions from Northwest Middle School students in Taneytown during a presentation on stem-cell research Tuesday afternoon. By Karen Kemp, Times Staff Writer
TANEYTOWN — When Matthew Schissler was working at Baugher's Restaurant more than two decades ago, he could have never predicted that he would one day help form a company that preserves stem cells for treating disease.
On Tuesday, the 1989 Westminster High School graduate and CEO of Cord Blood America used his career path as an analogy to describe the science behind stem cells to seventh-graders at Northwest Middle School.
Stem cells are cells with no particular identity or function, which have the ability to develop into any of the 220 types of cells in the human body by mirroring or replicating them, Schissler said.
"Everyone in this room kind of represents a stem cell," he said, referring to the many career paths the students could one day choose.
Schissler, who lives in Santa Monica, Calif., visited Carroll County this week during a trip to his company's sales office in Philadelphia.
Northwest Middle science teacher Erin Thomas, also a 1989 WHS graduate, was planning their class's 20-year reunion when she learned what Schissler did for a living.
Her students are now learning about cells and disease prevention, so she invited him to speak to her classes about stem cells and their ability to save lives.
Cord Blood America stores cryogenically frozen umbilical cord blood, which contains stem cells that can be used to treat about 70 different diseases, according to Schissler. Draining the blood from the umbilical cord is a five-minute procedure, but it must be done within 24 hours of birth in order to preserve the cells, he told the students.
He said the oldest sample of umbilical cord blood is 20 years old. In the past nine years, there have been close to 10,000 cord blood transplants to treat diseases, mostly immune disorders.
Schissler said he wanted to pique students' interests in a topic they might not fully understand and possibly inspire them to pursue careers in science.
"They're actually at the beginning of what could be considered a medical revolution," he said.
Thomas said her students understand what cells are, and she thinks they were able to grasp the topics in Schissler's presentation.
Since he started the company in 2003, Schissler has given similar talks to other students on the body's ability to heal itself with its own stem cells. He said he had to carefully tailor his discussion to his audience.
"It's the first time I've spoken to students this young," he said.
Reach staff writer Karen Kemp at 410-857-7890 or karen.kemp@carrollcountytimes.com.
Cord Blood America Financials; Stem Cell Sector Up 9 Percent
Cord Blood America Announces 2008 Financial Results
SANTA MONICA, Calif., April 16 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that revenues for the stem cell collection portion of its business increased 8.7 percent, or $0.3 million, to $3.4 million for the fiscal year ended December 31, 2008.
The increase was due to organic growth in the collection of more umbilical cord blood samples, said Matthew Schissler, Cord Blood America Founder and CEO. Revenue for the Company decreased to $4.2 million for the fiscal year, a drop entirely attributable to a decrease in emphasis on Rain, the Company's advertising operations, with Cord Blood America centrally focused on growing its stem cell collection operations.
Gross profit increased approximately $350,000 to $2.3 million in 2008, which was 56 percent of revenues, up from 34 percent in 2007. "Economies of scale are really starting to improve our financial performance," Mr. Schissler said. "Expenses were down 37.2 percent, or $2.2 million, for the fiscal year as Cord Blood America continues to streamline and reduce expenses in all areas."
"We accomplished much in 2008 and we look forward to continuing the positive trends throughout 2009," Mr. Schissler said.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
CC Question - I understand that you had an extensive conversation at Battlefield with Lt. Col. Springer. Can you please tell us if there are any immediate plans to begin work at Walter Reed?
Cord Blood America (OTC BB) On Money TV
Hear and see Matt Schissler, Cord Blood America's CEO and founder, talk about the Company's aggressive acquisition strategy and its Health Insurance Partnerships at